The search for genomic biomarkers of response to immunotherapy in ovarian cancer Editorial

   


Authors: Al-Rawi, D. H.; Rusk, N.; Friedman, C. F.
Title: The search for genomic biomarkers of response to immunotherapy in ovarian cancer
Abstract: Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698. ©2023 American Association for Cancer Research.
Keywords: genetics; ovarian neoplasms; progression free survival; tumor marker; immunotherapy; ovary tumor; genomics; progression-free survival; humans; human; female; biomarkers, tumor
Journal Title: Clinical Cancer Research
Volume: 29
Issue: 9
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2023-05-01
Start Page: 1645
End Page: 1647
Language: English
DOI: 10.1158/1078-0432.Ccr-23-0048
PUBMED: 36826422
PROVIDER: scopus
PMCID: PMC10159911
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159245337&doi=10.1158%2f1078-0432.CCR-23-0048&partnerID=40&md5=6a2f5d959e9c18f04eac60f38c331de7
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Claire F. Friedman -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Claire Frances Friedman
    118 Friedman
  2. Nicole Rusk
    11 Rusk
  3. Duaa Al-Rawi
    8 Al-Rawi
Related MSK Work